Windward Bio’s WIN378 Delivers Positive Phase 2 Asthma Data as Twice-Yearly Anti-TSLP Antibody Moves Into Phase 3
Windward Bio has reported positive interim Phase 2 results for WIN378, also known as HBM9378 or SKB378, showing sustained improvements in lung function and key inflammatory biomarkers after a single dose in patients with uncontrolled asthma. With a…
Clover Biopharma’s RSV-hMPV-PIV3 Combination Vaccines Deliver Encouraging Phase 2 Results in Older Adults
Clover Biopharmaceuticals has reported positive preliminary Phase 2 data for SCB-1022 and SCB-1033, two next-generation combination respiratory vaccines designed to protect older adults against multiple major respiratory viruses with a single shot. The…
CTTQ’s HER2 Bispecific ADC TQB2102 Hits Phase 3 Endpoints in HER2-Low Breast Cancer, Setting Up China Filing
Chia Tai Tianqing Pharmaceutical Group (CTTQ), a core subsidiary of Sino Biopharmaceutical, has reported a major late-stage clinical win for TQB2102 (rolditamig deuderuxtecan), its internally developed HER2 bispecific antibody-drug conjugate (ADC). The…
Akeso’s Ivonescimab Outshines Pembrolizumab on Overall Survival in Phase 3 HARMONi-2 Trial
China’s Akeso has reported another major clinical milestone for ivonescimab (AK112), its first-in-class PD-1/VEGF bispecific antibody, announcing that the drug demonstrated a statistically significant and clinically meaningful overall survival (OS)…
Genocury’s In Vivo CAR-T JY231 Shows Early Promise in Refractory Neurologic Autoimmune Diseases
A Chinese research team has reported encouraging early clinical results for JY231, an investigational lentiviral in vivo CD19 CAR-T therapy that generates therapeutic CAR-T cells directly inside the patient’s body, potentially eliminating two of…
ApicHope’s AR882 Beats Febuxostat in China Phase 3 Gout Trial, Meeting Primary Endpoint
China’s ApicHope Pharmaceutical Group has reported positive topline results from a Phase 3 clinical trial of AR882 (pozdeutinurad), its next-generation URAT1 inhibitor for gout, showing statistically significant superiority over febuxostat in lowering…
Ascletis Doses First Participant in Global Phase III Program of Oral GLP-1 Drug ASC30
Ascletis Pharma has dosed the first participant in its global Phase III AURORA clinical program evaluating ASC30, a once-daily oral small-molecule GLP-1 receptor agonist for chronic weight management, launching a roughly 4,600-patient registrational…
CSPC’s EGFR ADC SYS6010 Beats Chemotherapy in Phase 3 NSCLC Trial, Setting Stage for Potential Regulatory Filing
CSPC Pharmaceutical Group’s experimental EGFR-targeting antibody-drug conjugate SYS6010 has met the primary endpoint in the pivotal Phase III SYNSTAR-01 trial, significantly improving progression-free survival over platinum-based chemotherapy in…
Biokin’s Iza-Bren Hits Phase 3 PFS Endpoint in HR+/HER2− Breast Cancer, Marking 5th Phase 3 Success
Biokin Pharmaceutical’s first-in-class EGFR×HER3 bispecific antibody-drug conjugate izalontamab brengitecan (iza-bren; BL-B01D1) has delivered another positive Phase 3 readout, meeting the progression-free survival endpoint in previously treated…
Akeso’s Ivonescimab Beats Durvalumab Standard in Phase 3 Biliary Tract Cancer Trial
Akeso’s PD-1/VEGF bispecific antibody ivonescimab has delivered another major Phase 3 victory, this time outside lung cancer, demonstrating a statistically significant overall survival advantage over durvalumab plus chemotherapy in first-line advanced…